Alberto Ocaña-rekin lankidetzan egindako argitalpenak (105)

2024

  1. T-reg transcriptomic signatures identify response to check-point inhibitors

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Considerations for the clinical development of immuno-oncology agents in cancer

    Frontiers in immunology, Vol. 14, pp. 1229575

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers

    Cancers, Vol. 14, Núm. 18

  3. Genomic mapping of copy number variations influencing immune response in breast cancer

    Frontiers in Oncology, Vol. 12

  4. HER3 in cancer: from the bench to the bedside

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  5. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

  6. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

  7. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  8. Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates

    Frontiers in Immunology, Vol. 12

2021

  1. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. Generation of antibody‐drug conjugate resistant models

    Cancers, Vol. 13, Núm. 18

  3. Genomic correlates of dna damage in breast cancer subtypes

    Cancers, Vol. 13, Núm. 9

  4. Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer

    Cancers, Vol. 13, Núm. 16

  5. In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer

    Cellular Oncology, Vol. 44, Núm. 3, pp. 569-580

  6. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  7. Mapping of genomic vulnerabilities in the post-translational ubiquitination, sumoylation and neddylation machinery in breast cancer

    Cancers, Vol. 13, Núm. 4, pp. 1-23

  8. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  9. Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer

    Frontiers in Oncology, Vol. 11

  10. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8